K-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction

Pharmacogenomics Journal

Volumn 10, Issue 4, 2010, Pages 292-309

  Parry, R M ^a   Jones, W ^b   Stokes, T H ^c   Phan, J H ^a   Moffitt, R A ^a   Fang, H ^d   Shi, L ^e   Oberthuer, A ^f   Fischer, M ^f   Tong, W ^e   Wang, M D ^a  

^a EMORY UNIVERSITY   (United States)

^b Expression Analysis   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d ICF INTERNATIONAL   (United States)

^e NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cancer prediction; data analysis protocol; k nearest neighbor (KNN) models; MAQC II; parameter selection; predictable good performance

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CADHERIN; CENTROMERE PROTEIN A; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPHRIN RECEPTOR A5; ESTROGEN RECEPTOR; HOMEODOMAIN PROTEIN; MEMBRANE PROTEIN; MYC PROTEIN; OSTEOGENIC PROTEIN 1; PERIPHERAL MYELIN PROTEIN 22; SECRETOGRANIN II; SULFOTRANSFERASE; TRANSCRIPTION FACTOR TWIST; TUMOR SUPPRESSOR PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; DATA ANALYSIS; DISEASE FREE SURVIVAL; EXTERNAL VALIDITY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; INTERMETHOD COMPARISON; INTERNAL VALIDITY; K NEAREST NEIGHBOR; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; ANIMAL; BIOASSAY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; DNA MICROARRAY; FEMALE; GENETICS; PREDICTIVE VALUE; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; MULTIPLE MYELOMA; NEOPLASM STAGING; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955160229     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.56     Document Type: Article

References (50)

1. Shi L. MAQC-II Project: a comprehensive survey of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010; advance online publication doi:10.1038/nbt.1665.
2. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007; 8: 203-211.
3. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
4. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24: 5070-5078.
5. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002; 97: 77-87.
6. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. Gene expression-based survival prediction in lung adeno-carcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-827.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
8. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-469.
9. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102: 13550-13555.
10. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci USA 2008; 105: 9751-9756.
11. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039.
12. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
13. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-1235.
14. Bishop CM. Pattern Recognition and Machine Learning. Springer: New York, 2006, 738pp.
15. Duda RO, Hart PE, Stork DG. Pattern Classification, 2nd edn. Wiley: New York, 2001, 654pp.
16. DeRisi JL, Iyer VR, Brown PO. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 1997; 278: 680-686.
17. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
18. Aydn GB, Kutluk MT, Yalcn B, Buyukpamukcu M, Kale G, Varan A et al. Neuroblastoma in Turkish children: experience of a single center. J Pediatr Hematol Oncol 2009; 31: 471-480.
19. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 2000; 36: 901-908.
20. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
21. Volchenboum SL, Cohn SL. Are molecular neuroblastoma classifiers ready for prime time? Lancet Oncol 2009; 10: 641-642.
22. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009; 27: 1026-1033.
23. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10: 663-671.
24. Oberthuer A, Juraeva D, Li L, Kahlert Y, Westermann F, Elis R et al. Comparison of the performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010; 10: 258-266.
25. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 2000; 16: 412-424.
26. Ferri C, Hernández-Orallo J, Modroiu R. An experimental comparison of performance measures for classification. Pattern Recognit Lett 2009; 30: 27-38.
27. Cortes C, Mohri M. AUC optimization vs. error rate minimization. In: Thrun S, Saul L, Schoelkopf B (eds). Advances in Neural Information Processing Systems 16. The MIT Press: Cambridge, MA, 2004.
28. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007; 26: 1959-1970.
29. Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, Schackert HK et al. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 2005; 24: 5079-5088.
30. Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Jarvinen H et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26: 312-320.
31. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-372.
32. Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997; 19: 93-101.
33. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-230.
34. Edsjo A, Nilsson H, Vandesompele J, Karlsson J, Pattyn F, Culp LA et al. Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest 2004; 84: 406-417.
35. Luttikhuis ME, Powell JE, Rees SA, Genus T, Chughtai S, Ramani P et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 2001; 85: 531-537.
36. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
37. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004; 20: 1464-1465.
38. Farina AR, Tacconelli A, Cappabianca L, Cea G, Chioda A, Romanelli A et al. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells. Oncogene 2009; 28: 4075-4094.
39. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002; 20: 441-451.
40. Thorell K, Bergman A, Caren H, Nilsson S, Kogner P, Martinsson T et al. Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics 2009; 2: 53.
41. Lagergren A, Manetopoulos C, Axelson H, Sigvardsson M. Neuroblas-toma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression. BMC Cancer 2004; 4: 80.
42. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007; 30: 97-103.
43. Rabenau KE, O'Toole JM, Bassi R, Kotanides H, Witte L, Ludwig DL et al. DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity. Oncogene 2004; 23: 5056-5067.
44. Chung S, Furihata M, Tamura K, Uemura M, Daigo Y, Nasu Y et al. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene 2009; 28: 2849-2859.
45. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 2006; 6: 144.
46. Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res 2003; 63: 3511-3516.
47. Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C et al. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer 2008; 113: 1412-1422.
48. Li L, Hung AC, Porter AG. Secretogranin II: a key AP-1-regulated protein that mediates neuronal differentiation and protection from nitric oxide-induced apoptosis of neuroblastoma cells. Cell Death Differ 2008; 15: 879-888.
49. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. Br J Cancer 2006; 94: 13-17.
50. Sumantran VN, Brederlau A, Funa K. BMP-6 and retinoic acid synergistically differentiate the IMR-32 human neuroblastoma cells. Anticancer Res 2003; 23(2B): 1297-1303.